On May 29, Qingsong Health rose 6.03% in regular trading, trading at 24.96 HKD/share, with trading volume of 30.68 million HKD.

On the news front, the company recently announced a strategic partnership with premium general practice brand D&U Clinic, embedding its proprietary evidence-based medical AI agent ZhengYuanFang into high-net-worth C-end services including family member health management and corporate executive healthcare, accelerating its AI medical commercial closed-loop deployment.

Under the partnership, Qingsong Health will leverage its AIcare technology stack to provide AI-assisted support for D&U Clinic's general practitioners and specialist teams, enhancing standardization and response efficiency across health assessments, report interpretation, chronic disease management, and specialist referrals. The collaboration extends across the Greater Bay Area, integrating private physician services with domestic and international medical resources.

Meanwhile, Hong Kong's AI application sector saw elevated sentiment, with Zhipu AI surging over 40% cumulatively in three days to record highs, as capital shifts from model expectations toward real-world deployment scenarios. Qingsong Health, as the first and only AI medical product to pass the China Academy of Information and Communications Technology MedClaw evaluation, benefits from both sector linkage and policy catalysts.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)